When the Artery Opens but the Heart Stays Starved: Rethinking Microvascular Obstruction in Heart Attacks

One of the most frustrating paradoxes in modern cardiology is that a heart attack patient can leave the catheterization laboratory with a perfectly reopened coronary artery and still have a heart that is starved of oxygen. Primary percutaneous coronary intervention, or pPCI, remains the cornerstone of treatment for ST-segment elevation myocardial infarction, the most severe form of heart attack, and it is remarkably effective at restoring blood flow through the large epicardial vessels. Yet according to a new narrative review published in Frontiers in Cardiovascular Medicine by a team from the University of Verona and Sapienza University of Rome, adequate reperfusion at the tissue level is not achieved in up to half of these patients. The culprit is microvascular obstruction, or MVO, a failure of blood delivery in the tiny vessels that make up more than 90 percent of total coronary vascular resistance. Cardiac magnetic resonance studies have consistently tied MVO to adverse left ventricular remodeling, heart failure hospitalization, and increased long-term mortality, making it arguably the next frontier in heart attack care.

The pathophysiology of MVO is complex and dynamic, involving several interacting mechanisms rather than a single lesion. Distal embolization occurs when thrombotic and atherosclerotic debris, including platelets, fibrin, plaque components, and cholesterol crystals, migrate downstream from the culprit plaque, either spontaneously or during the intervention itself, plugging the microvasculature and triggering microinfarctions with local inflammatory responses. Ischemia-reperfusion injury adds another layer: when blood flow is restored after a period of deprivation, interstitial myocardial edema can compress capillaries and arterioles, worsening the very injury that reperfusion was meant to relieve. Inflammation contributes through the recruitment of inflammatory cells and the formation of neutrophil-platelet aggregates that physically obstruct microvessels, while endothelial swelling and intraluminal blebs narrow capillary lumens. Oxidative stress, altered hemodynamic forces, and autonomic dysregulation round out the picture, and the review emphasizes that microvascular dysfunction is closely interconnected with the epicardial circulation through both mechanical and humoral pathways.

Diagnosis of MVO remains a major bottleneck. The review carefully distinguishes related but non-interchangeable phenomena: MVO refers to structural obstruction and injury of the microcirculation, most specifically characterized by cardiac magnetic resonance; no-reflow describes the acute angiographic failure of myocardial perfusion; coronary microvascular dysfunction is a broader functional abnormality assessable with invasive or angiography-derived indices; and intramyocardial hemorrhage represents severe microvascular disruption with extravasation of red blood cells into the infarcted tissue. Current tools, chiefly cardiac magnetic resonance and the wire-based index of microcirculatory resistance, are limited by technical and logistical constraints. The angiography-derived version of that index, known as angio-IMR, has now demonstrated diagnostic and prognostic accuracy comparable to the invasive measurement and predictive value similar to CMR, and research by Duan and colleagues shows that integrating angio-IMR with CMR-assessed MVO significantly improves risk stratification, with the two parameters providing complementary rather than redundant information.

Emerging diagnostic technologies promise to bring microvascular assessment directly into the catheterization laboratory. The age-thrombus burden-index of microcirculatory resistance, or ATI score, developed by De Maria and colleagues, can be calculated before stenting and has been validated against CMR, predicting the likelihood of MVO and infarct size both acutely and at six months. Photon-counting computed tomography is another striking advance: in a recent head-to-head comparison, infarct size and MVO quantified by late iodine enhancement on PCCT correlated closely with CMR-derived late gadolinium enhancement, with strong agreement across coronary territories and viability thresholds. Perhaps most intriguing is the Controlled Flow Infusion, or CoFI, system, which characterizes the relationship between coronary flow and pressure that is markedly disrupted in the presence of MVO. A controlled infusion of Ringer’s lactate is delivered through a balloon positioned in the stented segment while intracoronary pressure is monitored, and a CoFI pressure threshold of 21.5 mmHg yielded 95 percent sensitivity, 91 percent specificity, and an area under the curve of 0.94 for MVO detection, all in a procedure requiring only a few minutes.

On the therapeutic side, the review organizes interventions by their predominant pathophysiological mechanism, starting with the thrombotic burden and distal embolization. Current European Society of Cardiology and American guidelines discourage routine thrombectomy, recommending it only as a selective or bailout strategy in the presence of high thrombus burden, impaired coronary flow, failed reperfusion, or hemodynamic instability. The evidence is mixed: the CHEETAH study supported the feasibility of sustained mechanical aspiration with high rates of thrombus removal and restored perfusion, and CMR work by Ismaiel and colleagues suggested aspiration thrombectomy may preserve microvascular integrity, but the landmark TASTE and TOTAL trials found no reduction in 30-day mortality with routine thrombus aspiration. Stent retrievers, originally developed for stroke, have shown promise as a bailout option for massive intracoronary thrombus in the RETRIEVE AMI randomized trial, though larger studies are needed before routine adoption. Intracoronary thrombolysis has produced similarly conflicting results, with some studies of low-dose prourokinase or streptokinase suggesting perfusion benefits while larger randomized trials of alteplase and prourokinase failed to improve MVO or six-month outcomes.

Sonothrombolysis, which uses high-mechanical-index ultrasound impulses delivered during an intravenous microbubble infusion to generate cavitation shear forces that dissolve thrombi, has generated genuine excitement. In the MRUSMI trial, sonothrombolysis applied before and after PCI in first STEMI patients was associated with higher epicardial recanalization rates, smaller infarct size, sustained improvements in left ventricular systolic function, and a reduced need for implantable defibrillators during follow-up, with effects emerging even before emergent PCI. Aguiar and colleagues found sonothrombolysis independently predicted favorable left ventricular remodeling over time, though a randomized trial by El Kadi and colleagues found no additional benefit when applied after PCI. The timing pattern is consistent with the broader theme that intervention within the biologically relevant window matters. Platelet inhibition also matters, since suboptimal response to dual antiplatelet therapy has been linked to greater late gadolinium enhancement and MVO on CMR and higher rates of major adverse cardiovascular events at one year, although whether more potent platelet inhibition specifically prevents MVO beyond its established role remains uncertain.

Intracoronary vasodilators and procedural timing strategies illustrate the persistent gap between surrogate endpoints and clinical benefit. A 2026 network meta-analysis of 13 randomized trials with 1,674 patients found that verapamil and epinephrine were associated with significantly higher odds of achieving final TIMI grade 3 flow, and ST-segment resolution improved with epinephrine, verapamil, and adenosine, yet none of the agents reduced major adverse cardiovascular events or mortality, likely because the analyses were underpowered. Nicorandil, which combines nitrate-like vasodilation with ATP-sensitive potassium-channel activation, showed encouraging effects on no-reflow and ejection fraction in meta-analyses, but evidence linking it to CMR-defined MVO remains limited. Deferred stenting, proposed to allow thrombus burden reduction before implantation, reduced no-reflow and intraprocedural thrombotic events in the DEFER-STEMI trial and lower distal embolization in DANAMI-3-DEFER angiographic substudies, but the MIMI trial and CMR substudies found no reduction in infarct size or CMR-defined MVO, and the main DANAMI-3-DEFER trial of 1,215 patients, along with its 10-year follow-up, showed no significant benefit on hard clinical outcomes.

Device-based strategies targeting reperfusion injury tell a story of bold ideas meeting rigorous testing. Pressure-controlled intermittent coronary sinus occlusion, or PiCSO, revives a concept first described in 1898, using cyclic balloon inflations in the coronary venous system to promote washout of deoxygenated blood, but the randomized PiCSO-AMI-I trial failed to reduce infarct size, MVO, or intramyocardial hemorrhage, and its use cannot currently be recommended. Myocardial cooling fared similarly: the COOL AMI-EU Pivotal Trial failed to reduce infarct size because systemic cooling prolonged ischemic time, and even selective intracoronary hypothermia, though feasible and safe in the EURO-ICE trial, did not significantly reduce infarct size. Supersaturated oxygen, by contrast, has advanced furthest, with the AMIHOT, AMIHOT-II, and IC-HOT studies showing smaller infarcts and favorable safety, leading to US FDA approval for anterior STEMI treated within six hours, and a pooled analysis by Falah and colleagues linking SSO2 to reduced MVO. Mechanical left ventricular unloading with catheter-mounted axial-flow pumps remains investigational, with the STEMI-DTU pivotal trial now evaluating whether unloading before reperfusion reduces infarct size.

Anti-inflammatory and metabolic approaches are advancing rapidly, though none is yet established for MVO specifically. Statins, with their pleiotropic effects on oxidative stress, inflammation, and endothelial function, improved TIMI flow and IMR in a recent meta-analysis of high-intensity regimens, and Reindl and colleagues showed that higher admission LDL cholesterol independently predicted greater MVO and worse outcomes, though dedicated randomized trials on CMR-defined MVO are lacking. The CANTOS trial demonstrated that the interleukin-1beta antibody canakinumab reduced major adverse cardiovascular events by 15 percent, with patients achieving the greatest IL-6 reduction experiencing a 52 percent reduction in cardiovascular mortality, and the RESCUE trial confirmed that the IL-6 antibody ziltivekimab lowers inflammation and thrombosis biomarkers, with the ongoing ARTEMIS trial now testing outcomes in acute myocardial infarction. Colchicine reduced cardiovascular events by 23 percent in COLCOT and 31 percent in LoDoCo2, earning FDA approval in June 2023, but these trials were not designed to assess MVO endpoints. C-reactive protein apheresis remains hypothesis-generating, with the CAMI-1 study suggesting potential cardioprotection in patients with large infarcts.

The review’s central conclusion is that the repeated failure of broadly applied cardioprotective strategies means MVO should no longer be treated as a uniform complication but as a heterogeneous, time-dependent syndrome requiring mechanism-based diagnosis and phenotype-guided therapy. No adjunctive intervention can currently be recommended for routine use solely to prevent or treat MVO on the basis of demonstrated clinical outcome benefit, and the authors argue that future trials must move beyond infarct size as a universal endpoint and adopt endotype-driven designs, enrolling patients according to their dominant mechanism of microvascular injury and testing specific or combined therapies within the appropriate therapeutic window. Forward-looking avenues include haptoglobin phenotyping for risk stratification, ion channels such as ASIC1a and selected transient receptor potential channels as cardioprotective targets, and cell-based strategies using mesenchymal stem cells and induced pluripotent stem cell-derived pericytes to preserve microvascular integrity. Whether this personalized framework can translate mechanistic insight into fewer heart failures and saved myocardium will be one of the defining questions of post-infarction research in the coming years.

Subject of Research: Strategies for diagnosing and treating coronary microvascular obstruction in patients with ST-elevation myocardial infarction

Article Title: Strategies to reduce microvascular obstruction and infarct size in patients with ST-elevation myocardial infarction

Article References: Rossignoli, C., Portolan, L., Pesarini, G., Fezzi, S., Galli, V., Pacchioni, A., Tavella, D., Ribichini, F., Scarsini, R., & Magistri, M. (2026). Strategies to reduce microvascular obstruction and infarct size in patients with ST-elevation myocardial infarction. Frontiers in Cardiovascular Medicine, 13, Article 1981540. https://doi.org/10.3389/fcvm.2026.1981540

Image Credits: AI Generated

DOI: 10.3389/fcvm.2026.1981540

Keywords: microvascular obstruction, STEMI, primary percutaneous coronary intervention, cardiac magnetic resonance, ischemia-reperfusion injury, sonothrombolysis, coronary microvascular dysfunction, angio-IMR, inflammation, oxidative stress, deferred stenting, supersaturated oxygen